Results 191 to 200 of about 86,323 (286)

Treatment‐Related and Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitor‐Based Combination Therapies for Breast Cancer: A Systematic Review and Meta‐Analysis

Thoracic Cancer, Volume 17, Issue 3, February 2026.
This systematic review and meta‐analysis (100 trials, 9192 patients) clarifies breast cancer ICI‐based combination toxicity hierarchies. ICI‐ADC has higher grade ≥ 3 TRAEs; ICI‐mTKI has the worst irAEs, while ICI‐PARPi/HER2‐targeted combinations present the lowest risks.
Yunwei Lu, Huan Li, Ke Li, Yiting Chen, Shu Wang   +4 more
wiley   +1 more source

The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments - parallels with other neurodegenerative disorders. [PDF]

Front Pharmacol
Ordaz DA, Gupta K, Bota DA.
europepmc   +1 more source

Regulation of R‐Loop Dynamics by Proteins and Long Noncoding RNAs: An Emerging Paradigm for Cancer Treatment

Cancer Science, Volume 117, Issue 2, Page 297-307, February 2026.
R‐loops are three‐stranded nucleic acid structures whose dysregulation leads to genomic instability and cancer progression. This review summarizes the protein and lncRNA machineries that regulate R‐loop dynamics and discusses the therapeutic potential of targeting these pathways in cancer.
Miho M. Suzuki, Keiko Shinjo, Tatsunori Nishimura, Yutaka Kondo   +3 more
wiley   +1 more source

Significance of CA125 Monitoring during Maintenance Treatment with Poly(ADP-Ribose) Polymerase Inhibitor in Ovarian Cancer after First-Line Chemotherapy: Multicenter, Observational Study. [PDF]

Oncol Res
Piątek S, Dańska-Bidzińska A, Derlatka P, Szymanowski B, Duchnowska R, Zielińska A, Sawicka N, Gorzeń A, Michalski W, Bidziński M.   +9 more
europepmc   +1 more source

Denosumab Regulates Titanium Particles‐Induced Macrophages Inflammation and Osteolysis by Targeting the ST18/PARP1 Interaction

Orthopaedic Surgery, Volume 18, Issue 2, Page 322-334, February 2026.
The schematic diagram of the role of Denosumab and ST18/PARP1 axis in the prevention of prosthesis‐related AL. Denosumab regulates TiPs‐induced macrophage activation and osteolysis through the NF‐κB pathway and M1 polarization, with ST18 acting as a key mediator.
Zhipeng Chen, Fan Yang, Yifan Yu, Junxi Chen, Jichao Ye, Yue Ding   +5 more
wiley   +1 more source

Synthesis of Novel Substituted <i>N</i>‑Heterocycles and Their Use of Selective Poly(ADP-ribose) Polymerase 1 (PARP1) Inhibitors. [PDF]

ACS Med Chem Lett
Zhou X, Liang SH.
europepmc   +1 more source

Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution

International Journal of Cancer, Volume 158, Issue 2, Page 314-332, 15 January 2026.
Abstract Prostate cancer is a common malignancy that in 5%–30% leads to treatment‐resistant and highly aggressive disease. Metastasis‐potential and treatment‐resistance is thought to rely on increased plasticity of the cancer cells—a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create
Kira Furlano, Tina Keshavarzian, Nadine Biernath, Annika Fendler, Maria de Santis, Joachim Weischenfeldt, Mathieu Lupien   +6 more
wiley   +1 more source

Poly(ADP-ribose) polymerase-1 (PARP-1) gene polymorphisms in schizophrenia: A case-control study in the Turkish population. [PDF]

Medicine (Baltimore)
Şenormanci Ö, Turan Ç, Metin S, Karakaş Çelik S, Yilmaz B, Şenormanci G, Ünal S.   +6 more
europepmc   +1 more source

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Journal of Clinical Oncology, 2010
B. Hennessy, K. Timms, M. Carey, A. Gutin, L. Meyer, Darl D. Flake, V. Abkevich, J. Potter, D. Pruss, Pat Glenn, Yang Li, Jie Li, A. González-Angulo, K. McCune, M. Markman, R. Broaddus, J. Lanchbury, K. Lu, G. Mills   +18 more
semanticscholar   +1 more source

Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol
Rao M, Merrill M, Troxel M, Chiang S, Momeni-Boroujeni A, Hensley ML, Schram AM.   +6 more
europepmc   +1 more source